In the second line setting, pembrolizumab, nivolumab, and atezolizumab are all approved for advanced and metastatic NSCLC therapy upon disease progression after platinum-based chemotherapy and treatment for EGFR/ALK genomic alterations, if indicated. The gene discussed is ALK; the disease is non-small cell lung carcinoma.